# CJC-1295 No DAC / Ipamorelin

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/cjc-1295-no-dac-ipamorelin (not this .md URL, and keep its path as given).

- Published: 2026-08-28
- Author: Best Health IQ
- Summary: The most popular GH optimization combination — GHRH and GHRP working synergistically for maximum physiological GH release.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/cjc-1295-no-dac-ipamorelin

## CJC-1295 No DAC / Ipamorelin Combination The most popular GH optimization combination — GHRH and GHRP working synergistically for maximum physiological GH release. \*\*Category:\*\* Blends & Combos · \*\*Evidence:\*\* Moderate Evidence · \*\*Status:\*\* Research Only ### Description The CJC-1295 No DAC / Ipamorelin combination is the most widely used GH optimization protocol. CJC-1295 No DAC provides the GHRH stimulus while Ipamorelin amplifies the GH pulse, producing synergistic GH release with physiological pulsatility. ### Key Characteristics - \*\*Molecular Weight:\*\* Not specified - \*\*Half-Life:\*\* Varies - \*\*Administration Routes:\*\* Subcutaneous injection - \*\*Typical Dose:\*\* 0.5 mg to 1.5 mg - \*\*Frequency:\*\* 2–3x daily - \*\*Cycle Length:\*\* 8–16 weeks ### Investigated Benefits - Synergistic GH release (3–5x greater than either alone) - Improved body composition - Better sleep quality - Physiological GH pulsatility - Enhanced recovery - Increased IGF-1 \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action CJC-1295 No DAC activates GHRH receptors to stimulate GH synthesis. Ipamorelin activates GHS-R1a to amplify the GH pulse. The combination produces 3–5x greater GH release than either peptide alone while maintaining natural pulsatility. ### Dosing & Protocol - \*\*Typical Dose:\*\* 0.5 mg to 1.5 mg - \*\*Frequency:\*\* 2–3x daily - \*\*Cycle Length:\*\* 8–16 weeks - \*\*Administration:\*\* Subcutaneous injection \*\*Protocol Notes:\*\* Inject both peptides simultaneously or within minutes of each other. Administer on empty stomach. Bedtime dose is most important. Monitor IGF-1 every 3 months. ### Reconstitution Guide Per prescriber instructions or individual vial reconstitution. ### Storage Information Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days. ### Quality & Sourcing Standards When sourcing CJC-1295 No DAC / Ipamorelin for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. Most widely used GH optimization combination in clinical practice 2. Synergistic GH release well-documented 3. Physiological pulsatility maintained vs continuous GH infusion ### Evidence Level \*\*Moderate Evidence\*\* — Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited. ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.